酒石酸布托啡诺复合舒芬太尼用于宫颈癌手术效果

Effect of butorphanol tartrate combined with sufentanil used during perioperative period of patients who had undergone cervical cancer operation

目的:探讨酒石酸布托啡诺复合舒芬太尼在宫颈癌手术围术期应用效果。方法:选取本院2016年5月-2019年12月收治的宫颈癌患者360例,简单随机分组法分为观察组和对照组各180例,观察组给予酒石酸布托啡诺复合舒芬太尼,对照组给予舒芬太尼,对比两组围术期血流动力学指标,术后不同时间点疼痛视觉模拟评分(VAS)和Ramsay镇静评分、不良反应、术后按压自控镇痛泵(PCIA)次数及镇痛满意率。结果:观察组入室前、麻醉时、麻醉后30min、术毕时时心率、收缩压、舒张压与对照组均无差异(P>0.05);术后6h、12h、24hVAS评分观察组(2.34±0.71分、2.25±0.63分、2.16±0.57分)低于对照组(2.86±0.71分、2.71±0.75分、2.58±0.68分),Rasmay评分(3.37±0.71分、3.48±0.75分、3.65±0.76分)高于对照组(3.05±0.67分、3.11±0.70分、3.26±0.81分)(均P<0.05);观察组恶心呕吐、头晕和嗜睡等不良反应总发生率(6.7%)低于对照组(17.2%),术后按压PCIA次数(10.3±3.3次)少于对照组(13.9±4.1次),镇痛满意率(95.6%)高于对照组(86.1%)(均P<0.05)。结论:酒石酸布托啡诺复合舒芬太尼对宫颈癌手术围术期镇痛效果较好,未对术中血流动力学造成明显影响,且减少不良反应发生,提高患者镇痛满意度。

Objective:To explore the effect of butorphanol tartrate combined with sufentanil used during perioperative period of patients who had undergone cervical cancer operation.Methods:A total of 360patients with cervical cancer were selected and randomly divided into observation group and control group(80cases in each group)from May 2016 to December 2019.The women in the observation group were given butorphanol tartrate combined with sufentanil,and the women in the control group were given sufentanil.The values of perioperative hemodynamic indexes,the visual analog pain score(VAS)at different time point,and Rasmay scores after operation,the rate of adverse reactions,the frequency of postopertative patient controlled intravenous analgesia(PCIA)pressed,and the analgesic satisfaction rate of the patients were compared between the two groups.Results:There were no significant differences in the values of heart rate,systolic blood pressure,and diastolic blood pressure of the patients before entering the operating room,during anesthesia,30min after anesthesia,and after the operation between the two groups(P>0.05).VAS scores of the patients in the observation group at postoperative 6h(2.34±0.71points),at postoperative 12h(2.25±0.63 points),and at postoperative 24h(2.16±0.57points)of the patients were significantly lower than those(2.86±0.71 points,2.71±0.75points,and 2.58±0.68points)of the patients in the control group.Rasmay scores of the patients in the observation group at postoperative 6h(3.37±0.71points),at postoperative 12h(3.48±0.75points),and at postoperative 24h(3.65±0.76points)of the patients were significantly higher than those(3.05±0.67points,3.11±0.70points,and 3.26±0.81points)of the patients in the control group(all P<0.05).The total incidence(6.7%)of the adverse reactions,such as nausea and vomiting,dizziness,and drowsiness of the patients in the observation group was significantly lower than that(17.2%)of the patients in the control group,the number of PCIA pressed after operation(10.3±3.3times)of the patients in the observation group was significantly less than that(13.9±4.1times)of the patients in the control group,and the analgesia satisfaction rate(95.6%)of the patients in the observation group was significantly higher than that(86.1%)of the patients in the control group(all P<0.05).Conclusion:Butorphanol tartrate combined with sufentanil has good perioperative analgesia effects for the patients with cervical cancer,which has no significantly influence on the intraoperative hemodynamics of the patients,and can reduce the occurrence of adverse reactions and can increase the analgesia satisfaction of the patients.